Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Conditions: High Grade Glioma; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Glioblastoma Interventions: Drug: Regadenoson 0.05mg; Drug: Regadensoson 0.1mg; Drug: Regadensoson 0.2mg; Drug: Regadensoson 0.4mg; Drug: Regadensoson 0.7mg; Drug: Regadensoson 1.0mg; Drug: Regadensoson 1.4mg Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Astrocytoma | Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Glioma | Lexiscan | Neurology | Research